Skip to main content
SpringerLink
Log in

Digitalis Glycosides

  • Chapter
Congestive Heart Failure

  • 458 Accesses

Abstract

Cardiac glycosides have played a prominent role in the therapy of congestive heart failure since William Withering codified its use in his classic monograph on the efficacy of the leaves of the common foxglove plant (Digitalis purpurea) in 1785. However, a controversy has arisen in the past two decades about whether the risks of digitalis preparations outweigh their benefits, particularly in patients with heart failure in sinus rhythm.1 The standard for clinical use of the cardiac glycosides in modern medicine was reflected in a debate between two eminent clinicians, who were also the coeditors of the Oxford Medicine, Henry Christian and Sir James Mackenzie. Sir James Mackenzie advocated the use of digitalis preparations only in those patients with heart failure who also had atrial arrhythmias, prompting the following response from Christian: “My views evidently differ from those of my fellow editor of the Oxford Medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Withering W. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other disease. In: Willius FA, Keys TE, eds. Classics of Cardiology. New York: Henry Schuman, Dover Publications; 1941;I:231–252.

    Google Scholar 

  2. Christian HA. Digitalis effects in chronic cardiac cases with regular rhythm in contrast to auricular fibrillation. Med Clin North Am. 1922;5:117–119.

    Google Scholar 

  3. Guntert TW, Linde HHA. Chemistry and structure-activity relationships of cardioactive steroids. In: Greeff K, ed. Handbook of Experimental Pharmacology, Vol. 56/I, Cardiac Glycosides. Berlin: Springer-Verlag; 1981: 13–24.

    Google Scholar 

  4. Marshall PG. Steroids: cardiotonic glycosides and aglycones; toad poisons. In: Coffy S, ed. Rodd’s Chemistry of Carbon Compounds, Vol. 2D, Steroids. Amsterdam: Elsevier; 1970.

    Google Scholar 

  5. Eisner DA, Smith TW. The Na-K pump and its effectors in cardiac muscle. In: Fozzard HA, Haber E, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. New York: Raven Press; 1992.

    Google Scholar 

  6. Thomas R, Gray P, Andrews J. Digitalis: its mode of action, receptor, and structure-activity relationships. In: Testa B, ed. Advances in Drug Research. New York: Academic Press; 1989:19.

    Google Scholar 

  7. Wiggers CJ, Stimson B. Studies on cardiodynamic action of drugs. III. The mechanism of cardiac stimulation by digitalis and g-strophanthin. J Pharmacol Exp Ther. 1927;30:251–269.

    CAS  Google Scholar 

  8. Sonnenblick EH, Williams JF Jr, Glick G, et al. Studies on digitalis. XV. Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart. Circulation. 1966;34:532–539.

    PubMed  CAS  Google Scholar 

  9. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980;303:1443–1448.

    PubMed  CAS  Google Scholar 

  10. Lee DC-S, Johnson RA, Bingham JB, et al. Heart failure in outpatients. A randomized trial of digoxin versus placebo. N Engl J Med. 1982;306:699–705.

    PubMed  CAS  Google Scholar 

  11. Reiter M. The positive inotropic action of cardiac glycosides on cardiac ventricular muscle. In: Greeff K, ed. Handbook of Experimental Pharmacology, Vol. 56/I, Cardiac Glycosides. Berlin: Springer-Verlag; 1981:187–210.

    Google Scholar 

  12. Koch-Weser J, Blinks JR. Analysis of the relation of the positive inotropic action of cardiac glycosides to the frequency of contraction of heart muscle. J Pharmacol Exp Ther. 1962;136:305–317.

    PubMed  CAS  Google Scholar 

  13. Marban E, Tsien RW. Enhancement of cardiac calcium current during digitalis inotropy: positive feedback regulation by intracellular calcium? J Physiol (Lond). 1982;329:589–614.

    PubMed  CAS  Google Scholar 

  14. Wier WG, Hess P. Excitation-contraction coupling in cardiac Purkinje fibers. Effects of cardiotonic steroids on the intracellular [Ca2+] transient, membrane potential, and contraction. J Gen Physiol. 1984;83:395–415.

    PubMed  CAS  Google Scholar 

  15. Morgan JP, Blinks JR. Intracellular Ca2+ transients in the cat papillary muscle. Can J Physiol Pharmacol. 1982;60:524–528.

    PubMed  CAS  Google Scholar 

  16. Kim D, Barry WH, Smith TW. Kinetics of ouabain binding and changes in cellular sodium content, 42K+ transport, and contractile state during ouabain exposure in cultured chick heart cells. J Pharmacol Exp Ther. 1984;231:326–333.

    PubMed  CAS  Google Scholar 

  17. Biedert S, Barry WH, Smith TW. Inotropic effects and changes in sodium and calcium contents associated with inhibition of monovalent cation active transport by ouabain in cultured myocardial cells. J Gen Physiol. 1979;74:479–494.

    PubMed  CAS  Google Scholar 

  18. Barry WH, Hasin Y, Smith TW. Sodium pump inhibition, enhanced Ca-influx via Na-Ca exchange, and positive inotropic response in cultured heart cells. Circ Res. 1985;56:231–241.

    PubMed  CAS  Google Scholar 

  19. Eisner DA, Lederer WJ, Vaughan-Jones RD. The quantitative relationship between twitch tension and intracellular sodium activity in sheep cardiac Purkinje fibers. J Physiol. 1984;355:251–266.

    PubMed  CAS  Google Scholar 

  20. Grupp I, Im WB, Lee CO, et al. Relation of sodium pump inhibition to positive inotropy at low concentrations of ouabain in rat heart muscle. J Physiol. 1985;360:149–160.

    PubMed  CAS  Google Scholar 

  21. Skou JC. The Na,K-pump. In: Fleischer S, Fleischer B, eds. Methods in Enzymology. San Diego, CA: Academic Press; 1988;156:1–28.

    Google Scholar 

  22. Pedersen PL, Carafoli E. Ion motive ATPases. Trends Biol Sci. 1987;12:146–150, 186–189.

    Google Scholar 

  23. Shull GE, Lingrel JB. Molecular cloning of the rat stomach (H+-K+)-ATPase. J Biol Chem. 1986;261:16788–16791.

    PubMed  CAS  Google Scholar 

  24. Shull GE, Young RM, Greeb G, et al. Amino acid sequences of the alpha and beta subunits of the Na,K-ATPase. In: Skou JC, Norby JG, Maunsbach AB, Esmann M, eds. The Na + , K + -Pump, Molecular Aspects. New York: Alan R Liss; 1988;l(Pt. A):3–18.

    Google Scholar 

  25. Gunteski-Hamblin AM, Greeb J, Shull GE. A novel Ca2+ pump expressed in brain, kidney and stomach is encoded by an alternative transcript of the slow-twitch muscle sarcoplasmic reticulum Ca-ATPase gene. J Biol Chem. 1988;263:15032–15040.

    PubMed  CAS  Google Scholar 

  26. Jorgensen PL, Collins JH. Localization of tryptic and chymotryptic cleavage sites in alpha-subunit of Na,K-ATPase. In: Skou JC, Norby JG, Maunsbach AB, Esmann M, eds. The Na + ,K + -Pump, Molecular Aspects. New York: Alan R Liss; 1988; 1(Pt. A):85–92.

    Google Scholar 

  27. Lytton J, MacLennan DH. Molecular cloning of cDNAs from human kidney coding for two alternatively spliced products of the cardiac Ca2+-ATPase gene. J Biol Chem. 1988;263:15024–15031.

    PubMed  CAS  Google Scholar 

  28. MacLennan DH, Brandi CJ, Korczak B, et al. Amino-acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature. 1985; 316:696–700.

    PubMed  CAS  Google Scholar 

  29. Shull GE, Schwartz A, Lingrel JB. Amino-acid sequence of the catalytic subunit of the (Na+ + K+)ATPase deduced from a complementary DNA. Nature. 1985; 316:691–695.

    PubMed  CAS  Google Scholar 

  30. Shull GE, Lane LK, Lingrel JB. Amino-acid sequence of the beta-subunit of the (Na+ + K+)ATPase deduced from a cDNA. Nature. 1986;321:429–431.

    PubMed  CAS  Google Scholar 

  31. Young RM, Shull GE, Lingrel JB. Multiple mRNAs from rat kidney and brain encode a single Na+,K+-ATPase beta subunit protein. J Biol Chem. 1987;262: 4905–4910.

    PubMed  CAS  Google Scholar 

  32. Forbush B, Kaplan J, Hoffman JF. Characterization of a new photoaffinity derivative of ouabain labeling of the large polypeptides and of a proteolipid compound of the NaK-ATPase. Biochemistry. 1978;17:3667–3675.

    PubMed  CAS  Google Scholar 

  33. Collins JH, Leszyk J. The “gamma subunit” of Na,K-ATPase: a small amphiphilic protein with a unique amino acid sequence. Biochemistry. 1987;26:8665–8668.

    PubMed  CAS  Google Scholar 

  34. Forbush B. Cardiotonic steroid binding to NaK-ATPase. In: Hoffman JF, Forbush B, eds. Current Topics in Membrane Transport. New York: Academic Press; 1983:167–201.

    Google Scholar 

  35. Wallick ET, Schwartz A. Interaction of cardiac glycosides with Na+,K+-ATPase. In: Fleischer S, Fleischer B, eds. Methods in Enzymology. San Diego, CA: Academic Press; 1988;156:201–213.

    Google Scholar 

  36. Langer GA. Relationship between myocardial contractility and the effects of digitalis on ionic exchange. Fed Proc. 1977;36:2231–2234.

    PubMed  CAS  Google Scholar 

  37. Eisner DA, Lederer WJ. The role of the sodium pump in the effects of potassium-depleted solutions on mammalian cardiac muscle. J Physiol. 1979;294:279–301.

    PubMed  CAS  Google Scholar 

  38. Lederer WJ, Eisner DA. The effects of sodium pump activity on the slow inward current in sheep cardiac Purkinje fibers. Proc R Soc Lond. 1982;B214:249–262.

    Google Scholar 

  39. Lee KS, Marban E, Tsien RW. Inactivation of calcium channels in mammalian heart cells. Joint dependence on membrane potential and intracellular calcium. J Physiol. 1985;364:395–411.

    PubMed  CAS  Google Scholar 

  40. Dagostino M, Lee CO. Neutral carrier Na+- and Ca2+-selective microelectrodes for intracellular application. Biophys J. 1982;40:199–207.

    PubMed  CAS  Google Scholar 

  41. Smith TW, Braunwald E, Kelly RA. Management of congestive heart failure. In: Braunwald E, ed. Heart Disease. 4th ed. Philadelphia: Saunders; 1992.

    Google Scholar 

  42. Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1986.

    Google Scholar 

  43. Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol. 1985;5(Suppl A):35A–42A.

    PubMed  CAS  Google Scholar 

  44. Rosen MR. Cellular electrophysiology of digitalis toxicity. J Am Coll Cardiol. 1985;5(Suppl A):22A–34A.

    PubMed  CAS  Google Scholar 

  45. Dhingra RC, Amat-Y-Leon F, Wyndham C, et al. The electrophysiological effects of ouabain on sinus node and atrium in man. J Clin Invest. 1975;56:555–562.

    PubMed  CAS  Google Scholar 

  46. Goodman DJ, Rossen RM, Ingham R, et al. Sinus node function in the denervated human heart: effects of digitalis. Br Heart J. 1975;37:612–618.

    PubMed  CAS  Google Scholar 

  47. Somberg JC, Smith TW. Localization of the neurally-mediated arrhythmogenic properties of digitalis. Science. 1979;204:321–323.

    PubMed  CAS  Google Scholar 

  48. Somberg JC, Risler TG, Smith TW. Neural factors in digitalis toxicity: protective effect of C-1 spinal cord transection. Am J Physiol. 1978;235:H531–H536.

    PubMed  CAS  Google Scholar 

  49. Rosen MR. Interactions of digitalis with the autonomic nervous system and their relationship to cardiac arrhythmias. In: Disturbances in Neurogenic Control of the Circulation. Bethesda, MD: American Physiological Society; 1981:251–263.

    Google Scholar 

  50. Packer M, ed. Role of the sympathetic nervous system in heart failure: basic mechanisms and clinical directions. Circulation.1990;82(Suppl I):I-1–I-13.

    Google Scholar 

  51. Ferguson DW, Berg WJ, Sanders JS, et al. Sympa-thoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation. 1989;80:65–77.

    PubMed  CAS  Google Scholar 

  52. Lindenbaum J, Rund DG, Butler VP Jr. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305:789–794.

    PubMed  CAS  Google Scholar 

  53. Halkin H, Sheiner LB, Peck CC, et al. Determinants of the renal clearance of digoxin. Clin Pharmacol Ther. 1975;17:385–394.

    PubMed  CAS  Google Scholar 

  54. Cogan JJ, Humphreys MH, Carlson CJ, et al. Acute vasodilator therapy increases renal clearance of digoxin in pateints with congestive heart failure. Circulation. 1981;64:973–976.

    PubMed  CAS  Google Scholar 

  55. Linday LA, Drayer DE, Khan MAA, et al. Pubertal changes in net renal tubular secretion of digoxin. Clin Pharmacol Ther. 1984;35:438–446.

    PubMed  CAS  Google Scholar 

  56. Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in biologic availability of digoxin from four preparations. N Engl J Med. 1971;285:1344–1347.

    PubMed  CAS  Google Scholar 

  57. Johnson BF, Lindenbaum J, Budnitz E, et al. Variability of steady-state digoxin kinetics during administration of tablets or capsules. Clin Pharmacol Ther. 1986;39:306–312.

    PubMed  CAS  Google Scholar 

  58. Leahey EB Jr, Reiffei JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA. 1978;240:533–534.

    PubMed  Google Scholar 

  59. Seiden R, Margolies MN, Smith TW. Renal and gastrointestinal excretion of ouabain in dog and man. J Pharmacol Exp Ther. 1974;188:615–623.

    Google Scholar 

  60. Cardiac Glycosides. Part II: pharmacokinetics and clinical pharmacology. In: Greeff K, ed. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag; 1981; 56.

    Google Scholar 

  61. Blatt CM, Marsh JD, Smith TW. Extracardiac effects of digitalis. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:209–215.

    Google Scholar 

  62. Sagar KB, Hanson EC, Powell WJ. Neurogenic coronary vasoconstrictor effects of digitalis during acute global ischemia in dogs. J Clin Invest. 1977;60:1248–1257.

    PubMed  CAS  Google Scholar 

  63. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med. 1974;57:63–68.

    PubMed  CAS  Google Scholar 

  64. Hougen TJ. Use of digoxin in the young. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:169–208.

    Google Scholar 

  65. Antman EM, Smith TW. Drug interactions with digitalis glycosides. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:65–82.

    Google Scholar 

  66. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol. 1985;5:82A–90A.

    PubMed  CAS  Google Scholar 

  67. Kuhlmann J, Marcin S. Effects of verapamil on pharmacokinetics and pharmacodynamics of digitoxin in patients. Am Heart J. 1985;110:1245–1250.

    PubMed  CAS  Google Scholar 

  68. Elkayam U, Parikh K, Torkan B, et al. Effect of dil-tiazem on renal clearance and serum concentration of digoxin in patients with cardiac disease. Am J Cardiol. 1985;55:1393–1395.

    PubMed  CAS  Google Scholar 

  69. Lessem J, Bellinetto A. Interaction between digoxin and calcium antagonists. Am J Cardiol. 1982;49:1025.

    Google Scholar 

  70. Moysey JO, Jaggarao NSV, Grundy EN, et al. Amio-darone increases plasma digoxin concentrations. Br Med J. 1981;282:272.

    CAS  Google Scholar 

  71. Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction during treatment of resistant cardiac arrhythmias. Am J Cardiol. 1982;49:1026.

    Google Scholar 

  72. Braunwald E. Effects of digitalis on the normal and the failing heart. J Am Coll Cardiol. 1985;5:51A–59A.

    PubMed  CAS  Google Scholar 

  73. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulation in heart failure. Circulation. 1991; 84:2181–2186.

    PubMed  CAS  Google Scholar 

  74. Cantelli I, Vitolo A, Lombardi G, et al. Combined hemodynamic effects of digoxin and Captopril in patients with congestive heart failure. Curr Ther Res. 1984;36: 323–331.

    Google Scholar 

  75. Bostrom PA, Andersson J, Johansson BW, et al. Hemodynamic effects of prenalterol and cardiac glycosides in patients with recent myocardial infarction. Eur J Clin Invest. 1984;14:175–180.

    PubMed  CAS  Google Scholar 

  76. Starr I, Luchi RJ. Blind study on the action of digitoxin on elderly women. Am Heart J. 1969;78:740–751.

    PubMed  CAS  Google Scholar 

  77. Dobbs SN, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure. Placebo controlled trial in outpatients. Br Med J. 1977;1:749–752.

    PubMed  CAS  Google Scholar 

  78. Fleg L, Gottlieb SH, Lakatta EG. Is digoxin really important in compensated heart failure? Am J Med. 1982;73:244–250.

    PubMed  CAS  Google Scholar 

  79. Taggart AJ, Johnston GD, McDevitt DG. Digoxin withdrawal after cardiac failure in patients with sinus rhythm. J Cardiovasc Pharmacol. 1983;5:229–234.

    PubMed  CAS  Google Scholar 

  80. Guyatt GH. The treatment of heart failure. A methodological review of the literature. Drugs. 1986;32:538–568.

    PubMed  CAS  Google Scholar 

  81. Gheorghiade M, St. Clair J, St. Clair C, et al. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol. 1987;9:849–857.

    PubMed  CAS  Google Scholar 

  82. Alicandri C, Fariello R, Boni E, et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol. 1987;9:S61–S67.

    PubMed  Google Scholar 

  83. Guyatt GH, Sullivan MJJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61:371–375.

    PubMed  CAS  Google Scholar 

  84. German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet. 1988;1:489–493.

    Google Scholar 

  85. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1–6.

    Google Scholar 

  86. Anon. Editorial. New evidence on xamoterol. Lancet. 1990;336:24.

    Google Scholar 

  87. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with Captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988;259:539–544.

    Google Scholar 

  88. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677–683.

    PubMed  CAS  Google Scholar 

  89. Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous Captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989; 13:134–142.

    PubMed  CAS  Google Scholar 

  90. Ribner HS, Zucker MJ, Stasior C, et al. Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin and their combination. Am Heart J. 1987;114:91–96.

    PubMed  CAS  Google Scholar 

  91. Cantelli I, Vitolo A, Lombardi G, et al. Combined hemodynamic effects of digoxin and Captopril in patients with congestive heart failure. Curr Ther Res. 1984; 36:323–331.

    Google Scholar 

  92. Sullivan M, Atwood JE, Myers J, et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol. 1989;13:1138–1142.

    PubMed  CAS  Google Scholar 

  93. Pugh SE, White NJ, Aronson JK, et al. Clinical, hemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long-term treatment. Br Heart J. 1989;61:529–539.

    PubMed  CAS  Google Scholar 

  94. Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin Therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled crossover trial. J Am Coll Cardiol. 1991;17: 743–751.

    PubMed  CAS  Google Scholar 

  95. Mohan P, Hii JTY, Wuttke RD, et al. Acute heart failure: determinants of outcome. Int J Cardiol. 1991; 32:365–376.

    PubMed  CAS  Google Scholar 

  96. Young JB, Uretsky BF, Shahidi E, et al. Multicenter, double-blind, placebo-controlled randomized withdrawal trial of the efficacy and safety of digoxin in patients with mild to moderate chronic heart failure not treated with converting enzyme inhibitors. J Am Coll Cardiol. 1992; 19:259A.

    Google Scholar 

  97. Packer M, Gheorghiade M, Young JB, et al. Randomized, double-blind, placebo-controlled, withdrawal study of digoxin in patients with chronic heart failure treated with converting-enzyme inhibitors. J Am Coll Cardiol. 1992;19:260A.

    Google Scholar 

  98. Kelly RA, Smith TW. Digoxin in heart failure: Implications of recent trials. J Am Coll Cardiol. 1993; (in Press).

    Google Scholar 

  99. Beiser GD, Epstein SE, Stampfer M, et al. Studies on digitalis. XVII. Effects of ouabain on the hemodynamic response to exercise in patients with mitral stenosis in normal sinus rhythm. N Engl J Med. 1968;278:131–137.

    PubMed  CAS  Google Scholar 

  100. Antman E. Medical management of the patient undergoing cardiac surgery. In: Braunwald E, ed. Heart Disease. 4th ed. Philadelphia: Saunders; 1992.

    Google Scholar 

  101. Johnson LW, Dickstein RA, Freuhan CT, et al. Prophylactic digitalization for coronary artery bypass surgery. Circulation. 1976;53:819–822.

    PubMed  CAS  Google Scholar 

  102. Tyras DH, Stothert JC Jr, Kaiser GC, et al. Supraventricular tachyarrhythmias after myocardial revascularization: a randomized trial of prophylactic digitalization. J Thorac Cardiovasc Surg. 1979;77:310–314.

    PubMed  CAS  Google Scholar 

  103. Antman EM, Friedman PL. Use of digitalis glycosides in the management of cardiac arrhythmias. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:127–151.

    Google Scholar 

  104. Surawicz B. Supraventricular arrhythmias. In: Messerli FH, ed. Cardiovascular Drug Therapy. Philadelphia: Saunders; 1990:1150–1166.

    Google Scholar 

  105. Bigger JT Jr, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:840–873.

    Google Scholar 

  106. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 1987;106:503–506.

    PubMed  CAS  Google Scholar 

  107. Simpson RJ, Foster JR, Woelfel AK, et al. Management of atrial fibrillation and flutter—a reappraisal of digitalis therapy. Postgrad Med. 1986;79:241–253.

    PubMed  Google Scholar 

  108. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J. 1985;290:9–11.

    CAS  Google Scholar 

  109. Zoble RG, Brewington J, Olukotun AY, et al. Use of beta-blockers as antiarrhythmic agents. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol. 1987;60:39D–45D.

    PubMed  Google Scholar 

  110. Ahuja RC, Sinha N, Saran RK, et al. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis—a randomized crossover study. Int J Cardiol. 1989;25:325–331.

    PubMed  CAS  Google Scholar 

  111. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225–227.

    PubMed  CAS  Google Scholar 

  112. Sellers TD, Bashore TM, Gallagher JJ. Digitalis in preexcitation syndrome—analysis during atrial fibrillation. Circulation. 1977;56:260–267.

    PubMed  Google Scholar 

  113. Kelly RA. Cardiac glycosides and congestive heart failure. Am J Cardiol. 1990;65:10E–16E.

    Google Scholar 

  114. Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984;26:414–458.

    Google Scholar 

  115. Hoffman BF, Bigger JT Jr. Digitalis and allied cardiac glycosides. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:814–839.

    Google Scholar 

  116. Lown B, Wyatt NF, Levine HD. Paroxysmal atrial tachycardia with block. Circulation. 1960;21:129–143.

    PubMed  CAS  Google Scholar 

  117. Fisch C, Knoebel SB. Accelerated junctional escape: a clinical manifestation of “triggered” automaticity. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology and Arrhythmias. New York: Grune & Stratton; 1985:467.

    Google Scholar 

  118. Eisendrath SJ, Sweeney MA. Toxic neuropsychiatrie effects of digoxin at therapeutic serum concentrations. Am J Psychiatry. 1987;144:506–507.

    PubMed  CAS  Google Scholar 

  119. Blatt CM, Marsh JD, Smith TW. The role of neural factors in digitalis intoxication. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:277–294.

    Google Scholar 

  120. Klausen T, Kjeldsen K, Norgaard A. Effects of denervation on sodium, potassium and [H3]ouabain binding in muscles of normal and potassium depleted rats. J Physiol. 1983;345:123–134.

    Google Scholar 

  121. Ferrier GR, Saunders JH, Méndez C. A cellular mechanism for the generation of ventricular arrhythmias by acetylstrophanthidin. Circ Res. 1973;32:600–609.

    PubMed  CAS  Google Scholar 

  122. Whang R, Qei TO, Watanabe A. Frequency of hypo-magnesemia in hospitalized patients receiving digitalis. Arch Intern Med. 1985;145:655–656.

    PubMed  CAS  Google Scholar 

  123. Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab fragments: experience in 26 cases. N Engl J Med. 1982;307:1357–1362.

    PubMed  CAS  Google Scholar 

  124. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285–1288.

    PubMed  CAS  Google Scholar 

  125. Vogel R, Kirch D, LeFree M, et al. Effects of digitalis on resting and isometric exercise myocardial perfusion in patients with coronary artery disease and left ventricular dysfunction. Circulation. 1977;56:355–359.

    PubMed  CAS  Google Scholar 

  126. Crawford MH, LeWinter MM, O’Rourke RA, et al. Combined propranolol and digoxin therapy in angina pectoris. Ann Intern Med. 1975;83:449–455.

    PubMed  CAS  Google Scholar 

  127. Lown B, Klein MD, Barr I, et al. Sensitivity to digitalis drugs in acute myocardial infarction. Am J Cardiol. 1972;30:388–395.

    PubMed  CAS  Google Scholar 

  128. Reicansky I, Conradson TB, Holmberg S, et al. The effect of intravenous digoxin on the occurrence of ventricular tachyarrhythmias in acute myocardial infarction in man. Am Heart J. 1976;91:705–711.

    PubMed  CAS  Google Scholar 

  129. Moss AJ, Davis HT, Conard DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64:1150–1156.

    PubMed  CAS  Google Scholar 

  130. Bigger JT, Fleiss JL, Rolnitzky LM, et al. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol. 1985;55:623–630.

    PubMed  Google Scholar 

  131. Ryan TJ, Bailey KR, McCabe CH, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease. Circulation. 1983;67:735–742.

    PubMed  CAS  Google Scholar 

  132. Madsen EB, Gilpin E, Henning H, et al. Prognostic importance of digitalis after acute myocardial infarction. J Am Coll Cardiol. 1984;3:681–689.

    PubMed  CAS  Google Scholar 

  133. Byington R, Goldstein S, and the BHAT Research Group. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the beta-blocker heart attack trial. J Am Coll Cardiol. 1985;6:976–982.

    PubMed  CAS  Google Scholar 

  134. Muller JE, Turi ZG, Stone PH, et al. Digoxin therapy and mortality after myocardial infarction: experience in the MILIS study. N Engl J Med. 1986;314:265–271.

    PubMed  CAS  Google Scholar 

  135. Szefler SJ, Jusko WJ. Decreased volume of distribution of digoxin in a patient with renal failure. Res Commun Chem Pathol Pharmacol. 1973;6:1095–1098.

    PubMed  CAS  Google Scholar 

  136. Friedman PL, Antman EM, Smith TW. Clinical management of digitalis toxicity. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:295–309.

    Google Scholar 

  137. Ditchey RV, Karliner JS. Safety of electrical cardioversion in patients without digitalis toxicity. Ann Intern Med. 1981;95:676–679.

    PubMed  CAS  Google Scholar 

  138. Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: final report of a multicenter study. Circulation. 1990;81:1744–1752.

    PubMed  CAS  Google Scholar 

  139. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17:590–598.

    PubMed  CAS  Google Scholar 

  140. Woolf AD, Wenger T, Smith TW, Lovejoy FH. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med. 1992;326:1739–1744.

    PubMed  CAS  Google Scholar 

  141. Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J. 1990;120:1189–1194.

    PubMed  CAS  Google Scholar 

  142. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69:1086–1196.

    Google Scholar 

  143. Smith TW. Serum and plasma cardiac glycoside concentrations: clinical use and misuse. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:153–167.

    Google Scholar 

  144. Doering W, Konig E, Sturm W. Digitalis intoxication: specificity and significance of cardiac and extracardiac symptoms. I. Patients with digitalis-induced arrhythmias. Z Kardiol. 1977;66:121–128.

    PubMed  CAS  Google Scholar 

  145. Eraker SA, Sasse L. The serum digoxin test and digoxin toxicity: a Bayesian approach to decision making. Circulation. 1981;64:409–420.

    PubMed  CAS  Google Scholar 

  146. Kelly RA, Smith TW. The search for the endogenous digitalis: an alternative hypothesis. Am J Physiol. 1989; 25:C737–C950.

    Google Scholar 

  147. Goto A, Yamada K, Yagi N, et al. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev. 1992;44:377–399.

    PubMed  CAS  Google Scholar 

  148. Hamlyn JM, Blaustein MP, Bova S, et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA. 1991;88:6259–6263.

    PubMed  CAS  Google Scholar 

  149. Gottlieb SS, Rogowski AC, Weinberg M, et al. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation. 1992;86:420–425.

    PubMed  CAS  Google Scholar 

  150. Kelly RA, Smith TW. Is ouabain the endogenous digitalis? Circulation. 1992;86:694–697.

    PubMed  CAS  Google Scholar 

  151. Graves SW, Brown B, Valdes R. An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med. 1983;99:604–608.

    PubMed  CAS  Google Scholar 

  152. Kramer HJ, Heppe M, Weiler E, et al. Further characterization of the endogenous natriuretic and digoxin-like immunoreacting activities in human urine: effects of changes in sodium intake. Renal Physiol. 1985;8:80–89.

    PubMed  CAS  Google Scholar 

  153. Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnant women. J Clin Endocrinol Metab. 1984;59:1070–1074.

    PubMed  CAS  Google Scholar 

  154. Seccombe DW, Pudek MR, Whitfield et al. Perinatal changes in a digoxin-like immunoreactive substance. Pediatr Res. 1984;18:1097–1099.

    PubMed  CAS  Google Scholar 

  155. Graves SW, Valdes R, Brown BA, et al. Endogenous digoxin-immunoreactive substance in human pregnancies. J Clin Endocrinol Metab. 1984;58:748–751.

    PubMed  CAS  Google Scholar 

  156. Vinge E, Helgessen-Rosendal S, Backstrom T. Progesterone, some progesterone derivatives and urinary digoxin-like substances from pregnant women in radio-immuno- and 85Rb uptake assays of digoxin. Pharmacol Toxicol. 1988;63:277–280.

    PubMed  CAS  Google Scholar 

  157. Koren G, Farine D, Grundmann H, et al. Endogenous digoxin-like substance (s) associated with uneventful and high-risk pregnancies. Dev Pharmacol Ther. 1988;11:82–87.

    PubMed  CAS  Google Scholar 

  158. Shrivastav P, Gill DS, D’Souza V, et al. Secretion of atrial natriuretic peptide and digoxin-like immunoreactive substance during pregnancy. Clin Chem. 1988;34: 977–980.

    PubMed  CAS  Google Scholar 

  159. Longerich L, Brent DA, Johnson RL, et al. Identification of progesterone and Cortisol as immunoreactive plasma digitalis-like factors in pregnancy. Res Commun Chem Pathol Pharmacol. 1988;59:383–393.

    PubMed  CAS  Google Scholar 

  160. Goodlin RC. Fetal endoxin and pregnancy complication. Am J Obstet Gynecol. 1988;158(Pt 1):529–530.

    PubMed  CAS  Google Scholar 

  161. Phelps SJ, Cochran EB, Gonzalez-Ruiz A, et al. The influence of gestational age and preeclampsia on the presence and magnitude of serum endogenous digoxin-like immunoreactive substance(s). Am J Obstet Gynecol. 1988;158:34–39.

    PubMed  CAS  Google Scholar 

  162. Weiner CP, Robillard JE. Atrial natriuretic factor, digoxin-like immunoreactive substance, norepinephrine, epinephrine, and plasma renin activity in human fetuses and their alteration by fetal disease. Am J Obstet Gynecol. 1988;159:1353–1360.

    PubMed  CAS  Google Scholar 

  163. Gonzalez AR, Phelps SJ, Cochran EB, et al. Digoxin-like immunoreactive substance in pregnancy. Am J Obstet Gynecol. 1987;157:660–664.

    PubMed  CAS  Google Scholar 

  164. Rauch AL, Buckalew VM Jr. Characterization of a competitive and reversible ligand to E2 conformation of Na,K-ATPase molecule. Biochem Biophys Res Commun. 1988;150:648–654.

    PubMed  CAS  Google Scholar 

  165. Kelly RA. Excretion of artifactual endogenous digitalislike factors. Am J Physiol. 1986;251:H205–H209.

    PubMed  CAS  Google Scholar 

  166. Diamandis EP, Papanastasiou-Diamandis A, Soldin SJ. Digoxin immunoreactivity in cord and maternal serum and placental extracts: partial characterization of immunoreactive substances by high-performance liquid chromatography and inhibition of Na+,K+-ATPase. Clin Biochem. 1985;18:48–55.

    PubMed  CAS  Google Scholar 

  167. Soldin SJ. Digoxin—issues and controversies. Clin Chem. 1986;32:5–12.

    PubMed  CAS  Google Scholar 

  168. Stone JA, Soldin SJ. Improved liquid chromatographic/immunoassay of digoxin in serum. Clin Chem. 1988; 34:2547–2551.

    PubMed  CAS  Google Scholar 

  169. Longerich L, Vasdev S, Johnson E, et al. Disposable-column radioimmunoassay for serum digoxin with less interference from metabolites and endogenous digitalislike factors. Clin Chem. 1988;34:2211–2216.

    PubMed  CAS  Google Scholar 

  170. Vinge E, Ekman R. Evaluation of crossreactivity of urinary digoxin-like substance in different radioimmunoassay. Ther Drug Monit. 1988;10:316–320.

    PubMed  CAS  Google Scholar 

  171. Lau BW, Valdes R Jr. Criteria for identifying endogenous compounds as digoxin-like immunoreactive factors in humans. Clin Chim Acta. 1988;175:67–77.

    PubMed  CAS  Google Scholar 

  172. Dasgupta A, Malik S, Ahmad S, et al. Mass spectrometry studies of a novel digoxin-like substance (DLIS-2) isolated from human plasma ultrafiltrate. Biochem Biophys Res Commun. 1988;152:1435–1440.

    PubMed  CAS  Google Scholar 

  173. Yannakou L, Diamandis EP, Souvatzoglou A. Effect of incubation time and temperature on the interference of digoxin-like immunoreactive substances in digoxin immunoassays. Ther Drug Monit. 1987;9:461–463.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ralph A. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas W. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Cardiology, Oregon Cardiac Transplant Program, Oregon Health Sciences University, Portland, OR, 97201-3098, USA

    Jeffrey D. Hosenpud M.D.

  2. Division of Cardiology, Oregon Health Sciences University, Portland, OR, 97201-3098, USA

    Barry H. Greenberg M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Kelly, R.A., Smith, T.W. (1994). Digitalis Glycosides. In: Hosenpud, J.D., Greenberg, B.H. (eds) Congestive Heart Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-8315-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-8315-4_22

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4613-8317-8

  • Online ISBN: 978-1-4613-8315-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation